

12 November 2024

BEXIMCO PHARMACEUTICALS LIMITED

Update on Interim Order following decision by the Supreme Court of Bangladesh

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBBD6TIOQGB56) provides an update on the Interim Order following the Supreme Court of Bangladesh's issued decision earlier today. This follows yesterday's announcement detailing the full-court hearing held on 11 November 2024 and the subsequent temporary suspension of trading on AIM.

The Bangladesh Supreme Court Appellate Division today allowed Beximco Pharma's appeal against the Interim Order regarding the appointment of a receiver to manage the Beximco group of companies (which included Beximco Pharma), and confirmed that its provisions will not apply to Beximco Pharma.

Following this decision, the Company's temporary suspension of trading on AIM has been lifted with immediate effect.

With regards to the Writ Petition, following this decision, the Bangladesh Supreme Court Appellate Division has instructed the High Court to resolve the pending case within two weeks.

Further announcements will be made in due course.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott / Adam Dawes
Tel: +44 (0) 20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson
Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Sam Purewal
Tel: +44 (0) 20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUUSKRSWUAARA